1. 1441PPhase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026. (23rd October 2018) Authors: Kawashima1, Y; Fukuhara, T; Furuya, N; Saito, H; Watanabe, K; Iwasawa, S; Tsunezuka, Y; Yamaguchi, O; Okada, M; Yoshimori, K; Nakachi, I; Gemma, A; Azuma, K; Hagiwara, K; Nukiwa, T; Morita, S; Kobayashi, K; Maemondo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗